{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:38:37Z","timestamp":1784299117393,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10557-019-06917-6","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T07:02:31Z","timestamp":1575442951000},"page":"755-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population"],"prefix":"10.1007","volume":"33","author":[{"given":"Dusty","family":"Lisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrina","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ombengi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"issue":"9646","key":"6917_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(08)61554-8","volume":"372","author":"DT Nash","year":"2008","unstructured":"Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet. 2008;372(9646):1335\u201341.","journal-title":"Lancet"},{"key":"6917_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ijcard.2016.10.102","volume":"227","author":"K Banerjee","year":"2017","unstructured":"Banerjee K, et al. Role of ranolazine in cardiovascular disease and diabetes: exploring beyond angina. Int J Cardiol. 2017;227:556\u201364.","journal-title":"Int J Cardiol"},{"issue":"4","key":"6917_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.amjcard.2017.11.021","volume":"121","author":"BW Gilbert","year":"2018","unstructured":"Gilbert BW, et al. Antihyperglycemic and metabolic effects of ranolazine in patients with diabetes mellitus. Am J Cardiol. 2018;121(4):509\u201312.","journal-title":"Am J Cardiol"},{"issue":"5","key":"6917_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/1060028016631757","volume":"50","author":"L Greiner","year":"2016","unstructured":"Greiner L, Hurren K, Brenner M. Ranolazine and its effects on hemoglobin A1C. Ann Pharmacother. 2016;50(5):410\u20135.","journal-title":"Ann Pharmacother"},{"key":"6917_CR5","doi-asserted-by":"crossref","unstructured":"Zeng X, et al. Efficacy and safety of ranolazine in diabetic patients: a systematic review and meta-analysis. Ann Pharmacother. 2017:1060028017747901.","DOI":"10.1177\/1060028017747901"},{"issue":"20","key":"6917_CR6","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","volume":"113","author":"BR Chaitman","year":"2006","unstructured":"Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462\u201372.","journal-title":"Circulation"},{"issue":"5","key":"6917_CR7","doi-asserted-by":"publisher","first-page":"H1923","DOI":"10.1152\/ajpheart.00173.2009","volume":"297","author":"AK Dhalla","year":"2009","unstructured":"Dhalla AK, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297(5):H1923\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10","key":"6917_CR8","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.2337\/db13-1562","volume":"63","author":"AK Dhalla","year":"2014","unstructured":"Dhalla AK, et al. Blockade of Na+ channels in pancreatic alpha-cells has antidiabetic effects. Diabetes. 2014;63(10):3545\u201356.","journal-title":"Diabetes"},{"issue":"1","key":"6917_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1124\/jpet.110.176396","volume":"337","author":"Y Ning","year":"2011","unstructured":"Ning Y, et al. Ranolazine increases beta-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther. 2011;337(1):50\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"20","key":"6917_CR10","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1113\/jphysiol.2013.257246","volume":"591","author":"Z Fu","year":"2013","unstructured":"Fu Z, et al. Ranolazine recruits muscle microvasculature and enhances insulin action in rats. J Physiol. 2013;591(20):5235\u201349.","journal-title":"J Physiol"},{"issue":"1","key":"6917_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","volume":"27","author":"AD Timmis","year":"2006","unstructured":"Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27(1):42\u20138.","journal-title":"Eur Heart J"},{"issue":"15","key":"6917_CR12","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","volume":"119","author":"DA Morrow","year":"2009","unstructured":"Morrow DA, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032\u20139.","journal-title":"Circulation"},{"issue":"5","key":"6917_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12629","volume":"18","author":"J Pettus","year":"2016","unstructured":"Pettus J, et al. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016;18(5):463\u201374.","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"6917_CR14","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.jacc.2017.02.056","volume":"69","author":"AC Fanaroff","year":"2017","unstructured":"Fanaroff AC, et al. Ranolazine after incomplete percutaneous coronary revascularization in patients with versus without diabetes mellitus: RIVER-PCI Trial. J Am Coll Cardiol. 2017;69(18):2304\u201313.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"6917_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cpdd.174","volume":"4","author":"J Zack","year":"2015","unstructured":"Zack J, et al. Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. Clin Pharmacol Drug Dev. 2015;4(2):121\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"6917_CR16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2337\/dc14-2629","volume":"38","author":"RH Eckel","year":"2015","unstructured":"Eckel RH, et al. Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care. 2015;38(7):1189\u201396.","journal-title":"Diabetes Care"},{"issue":"6","key":"6917_CR17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2337\/dc09-2334","volume":"33","author":"JW Chisholm","year":"2010","unstructured":"Chisholm JW, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010;33(6):1163\u20138.","journal-title":"Diabetes Care"},{"key":"6917_CR18","first-page":"A316","volume":"60","author":"M Kipnes","year":"2011","unstructured":"Kipnes M, et al. A study to assess the metabolic effects of ranolazine when added to ongoing non-insulin medical therapy in subjects with type 2 diabetes mellitus (T2DM). Diabetes. 2011;60:A316.","journal-title":"Diabetes"},{"issue":"1","key":"6917_CR19","first-page":"OC01","volume":"9","author":"S Sandhiya","year":"2015","unstructured":"Sandhiya S, et al. Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease\u2014a randomized controlled trial. J Clin Diagn Res. 2015;9(1):OC01\u20135.","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"6917_CR20","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1161\/01.RES.0000086964.07404.A5","volume":"93","author":"GD Lopaschuk","year":"2003","unstructured":"Lopaschuk GD, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93(3):e33\u20137.","journal-title":"Circ Res"},{"issue":"5","key":"6917_CR21","first-page":"44","volume":"35","author":"L Greiner","year":"2018","unstructured":"Greiner L, Hurren K, Brenner M. The effects of ranolazine on hemoglobin A1c in a veteran population. Fed Pract. 2018;35(5):44\u20138.","journal-title":"Fed Pract"},{"key":"6917_CR22","unstructured":"RANEXA\u00ae (ranolazine) extended-release tablets [package insert]. Foster City: Gilead Sciences, Inc; 2016."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06917-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-019-06917-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06917-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T16:18:41Z","timestamp":1665159521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-019-06917-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6917"],"URL":"https:\/\/doi.org\/10.1007\/s10557-019-06917-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"4 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}